(Q37957494)

25 August 2017

Modelling of Parkinson's disease in mice (English)

1 reference

Marie-Françoise Chesselet

25 August 2017

1 reference

series ordinal

1

object named as

Marie-Françoise Chesselet

1 reference

25 August 2017

Franziska Richter

2

1 reference

25 August 2017

1 December 2011

1 reference

25 August 2017

1 reference

25 August 2017

10

1 reference

25 August 2017

12

1 reference

25 August 2017

1108-1118

1 reference

Risk tables for parkinsonism and Parkinson's disease.

25 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Priorities in Parkinson's disease research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

The scientific and clinical basis for the treatment of Parkinson disease (2009).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Parkinson's Disease: Genetics and Pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Genetic mouse models of Parkinson's disease The state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Parkinson's disease: a model dilemma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Imaging dopamine transporters in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Neuroimaging in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Neurotoxic in vivo models of Parkinson's disease recent advances.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

MPTP neurotoxicity: an overview and characterization of phases of toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Parkinson's disease risk from ambient exposure to pesticides

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Genetic analysis of pathways to Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Olfactory deficits in mice overexpressing human wildtype alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Circadian dysfunction in a mouse model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Forebrain overexpression of alpha-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Neuropathology in mice expressing human alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Selective noradrenergic vulnerability in α-synuclein transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Non-motor behavioural impairments in parkin-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

DJ-1-deficient mice show less TH-positive neurons in the ventral tegmental area and exhibit non-motoric behavioural impairments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Genetic animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Transgenic animal models of neurodegeneration based on human genetic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Impaired in vivo dopamine release in parkin knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

A timeline for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

alpha-Synucleinopathy models and human neuropathology: similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Mitochondria: the next (neurode)generation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

PINK1-dependent recruitment of Parkin to mitochondria in mitophagy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Behavioral phenotyping of mouse models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

The challenge of non-motor symptoms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Gait alterations in healthy carriers of the LRRK2 G2019S mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Dopamine turnover increases in asymptomatic LRRK2 mutations carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

Protein aggregate spreading in neurodegenerative diseases: problems and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

SNCA variant associated with Parkinson disease and plasma alpha-synuclein level

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970227-7

7 January 2021

10.1016/S1474-4422(11)70227-7

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22094131